Catalent Pharma Solutions

Catalent, Supernus partner for supply of Trokendi XR

Monday, September 23, 2013 01:38 PM

Catalent Pharma Solutions, a global drug delivery technology and advanced supply solutions company, and Supernus Pharmaceuticals have entered into an agreement by which Catalent is the supplier of Trokendi XRTM extended release capsules for Supernus.

More... »

Catalent, Biota Pharmaceuticals expand alliance

Tuesday, July 16, 2013 09:30 AM

Catalent Pharma Solutions, a global development solutions and advanced drug delivery technologies company, and Biota Pharmaceuticals have allied to develop and provide filling and packaging capabilities to supply clinical trial materials of laninamivir octanoate, a first-in-class, inhaled, long-acting neuraminidase inhibitor being developed by Biota to treat influenza A and B viruses.

More... »

Catalent Pharma Solutions expands manufacturing facility

Friday, June 14, 2013 01:41 PM

Catalent Pharma Solutions, a global drug delivery technology and advanced supply solutions company, has announced an expansion of its controlled release drug manufacturing facility in Winchester, Ky. Catalent will invest nearly $35 million to expand the 100,000-square-foot facility by almost 80,000 square feet of modern manufacturing space, and will add as many as 90 new employees.

Opened in 1992, Catalent's Winchester facility focuses on advanced oral controlled-release drug formulation and manufacturing, and has launched over 100 products for Catalent's pharmaceutical and consumer health customers.

More... »

Catalent Biologics opens new single-use biomanufacturing Center of Excellence

Monday, April 29, 2013 01:58 PM

Catalent Pharma Solutions, a provider of drug and biologic development services, has officially open its new, state-of-the-art biomanufacturing Center of Excellence in Madison, Wisc.

More... »

Catalent Biologics expands into ADCs through license with Redwood Bioscience

Tuesday, April 16, 2013 10:34 AM

Catalent Pharma Solutions has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs).

More... »

Catalent announces major China expansion with two new facilities

Monday, March 11, 2013 10:09 AM

Catalent Pharma Solutions, a global drug development solutions provider, announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses. 

More... »

Catalent invests $20M to expand inhalation capabilities

Monday, January 14, 2013 12:04 PM

Catalent Pharma Solutions, Somerset, N.J.-based developer of solutions and drug delivery technology, is investing $20 million to expand its inhalation drug development, delivery and supply capabilities by enhancing its Inhalation Center of Excellence in Research Triangle Park in North Carolina. The investment will focus on expanding pressurized Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities as well as other enhancements to the facility.

More... »

Catalent, UMN Pharma collaborate on biosimilar development, production in Japan

Monday, December 17, 2012 11:35 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, has signed an agreement to provide UMN Pharma, a Japanese pharmaceutical company, a broad range of biosimilar cell lines using Catalent's proprietary GPEx technology.

More... »

Catalent Pharma launches Catalent Applied Drug Delivery Institute

Monday, October 22, 2012 11:38 AM

Catalent Pharma Solutions, a developer of solutions and advanced drug delivery technologies, has launched its Catalent Applied Drug Delivery Institute.

More... »

Catalent Pharma and CTC BIO to partner in South Korea

Monday, September 17, 2012 11:21 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, and CTC Bio, a drug and service provider based in Seoul, South Korea, have entered into a collaboration to provide optimal solutions to South Korean pharmaceutical companies seeking to commercialize solid oral dose and controlled release products in the U.S. and Europe.

More... »